Lumenis Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Lumenis's estimated annual revenue is currently $446.5M per year.(i)
  • Lumenis's estimated revenue per employee is $251,000

Employee Data

  • Lumenis has 1779 Employees.(i)
  • Lumenis grew their employee count by -3% last year.

Lumenis's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Personal Assistant To VPReveal Email/Phone
3
VP, HRReveal Email/Phone
4
VP Sales, US VisionReveal Email/Phone
5
VP Finance and Operations - AmericasReveal Email/Phone
6
VP OperationsReveal Email/Phone
7
VP Aesthetics, North AmericaReveal Email/Phone
8
ControllerReveal Email/Phone
9
Head Sales and Education Vision DACHReveal Email/Phone
10
ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$117.5M4685%N/AN/A
#2
$300M8232%$24.5MN/A
#3
$93.4M3726%N/AN/A
#4
$222M110952%$90.5MN/A
#5
$84.2M28919%N/AN/A
Add Company

What Is Lumenis?

Energy to Healthcare\r\n\r\nLumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). \r\n\r\nFor nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. \r\n\r\nOur drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century.\r\n\r\nA Leader with Great Assets in Attractive Growing Markets\r\n\r\nInnovative technology: Over 270 registered patents and more than 100 FDA clearances.\r\nGlobal reach: Active installed base of more than 80,000 systems and presence in over 100 countries.\r\n\r\nStrong brand: The Lumenis name and brand are associated with high quality among consumers.\r\n\r\nPartnership with key opinion leaders (KOL’s): Strong KOL support and commitment to research and development.

keywords:N/A

N/A

Total Funding

1779

Number of Employees

$446.5M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lumenis News

2022-04-20 - Medical Laser Devices Market Size, Outlook And Forecast ...

Photomedex, Lumenis, Ellex, Biolase, Boston Scientific, Quantel, Topcon, Sciton, Alma Lasers, Photomedex. This comprehensive Medical Laser Devices Market...

2022-04-20 - Medical Surgical Lasers Market Size, Outlook And Forecast ...

Cynosure, Lumenis, Alma Lasers, Abbott Laboratories, Boston Scientific, IPG Photonics, Spectranetics, Biolitec AG, Fotona d.o.o., BISON MEDICAL.

2022-04-20 - Aesthetic Laser Market Size, Scope And Outlook | Aerolase ...

Aerolase Corp., Lumenis Ltd., El. En SpA, Cynosure Cutera Alma Lasers, Sciton Sharplight Technologies Ltd., Solta Medical and Syneron...

2021-08-17 - Lumenis Raises The Bar For Aesthetic Outcomes With SmoothGlo™

LOS ANGELES, Aug. 17, 2021 /PRNewswire/ -- Lumenis, Ltd., the world's largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications is proud to announce the launch of SmoothGlo, a novel, nonsurgical approach to addressing the three most visible signs of aging ...

2021-04-29 - Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™ USA - English USA - English

YOKNE'AM ILLIT, Israel, April 29, 2021 /PRNewswire/ -- Lumenis Ltd., the world's largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authoriza ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$364.4M179531%N/A
#2
$603.1M191710%$578.7M
#3
$417.2M20556%N/A
#4
$736.2M23408%$14M
#5
$687.9M23586%$53M